Cardiovascular Disorder and Diabetes and India


India, the largest country in the South-Asia, is also the largest contributor to the non-communicable disease (NCD) burden. Several studies conducted over the last two decades have revealed the high total burden of diabetes, hypertension, and dyslipidaemia in India. he Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study, a cross-sectional population-based survey, assessed a representative sample of individuals aged 20 years and older drawn from urban and rural areas of 31 states, union territories, and the National Capital Territory of India. total of 113 043 individuals (79 506 from rural areas and 33 537 from urban areas) participated in the ICMR-INDIAB study between Oct 18, 2008, and Dec 17, 2020. The study reported that the prevalence in urban population as following1:

  • Dysglycaemia (diabetes and prediabetes) : 31.8%
  • Hypertension : 40.7%
  • Dyslipidaemia : 82.9%

Burden of Cardiovascular Diseases in India

According to the Global Burden of Disease study age-standardized estimates (2010)2

  • 24.8% of all deaths in India are attributable to CVD.
  • 30%–42% proportion of mortality attributable to CVD
  • Age-standardized CVD mortality rate is 255–525 per 100000 population in men and 225–299 per 100000 population in women.

Youngsters Need to take Care!!!!

  • Premature mortality in terms of years of life lost because of CVD in India increased by 59%, from 23.2 million (1990) to 37 million (2010).2
  • CVD deaths occur before the age of 70 years2: India : 52%; Western populations : 23%
  • The prevalence of Heart Failure reported to be 22.5% 30 years and 14.9% above 50 years, reflecting the young population of HF.3

Discover the HEART SECRETS of Young India from their Genes

Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. Genetic testing is informative and useful for the clinical management of various inherited cardiovascular diseases such as cardiomyopathies, arrhythmic disorders, thoracic aortic aneurysms and dissections, and familial hypercholesterolemia (FH) as per statement from American Heart Association.

MyDNA Cardio Genguard is a DNA based genetic test which helps to gain information regarding the predisposition to heart diseases and other related conditions. It also covers individual’s body response to diabetes and cardiovascular diseases medications. It can cover the following to assess the risk :

  • Cardiovascular Diseases : Atrial Fibrillation, Coronary Heart Disease, Stroke, Hypertrophic Cardiomyopathy, Venous thromboembolism (VTE), Sudden Cardiac Arrest, Long QT Interval
  • Endocrine Disorders: Type I diabetes and Type II diabetes
  • Drug Responses: Glimepiride, Glipizide, Glyburide, Propafenone, Rosuvastatin, Clopidogrel, Chlorpropamide, Acenocoumarol, Phenprocoumon, Atorvastatin, Metformin, Warfarin, Simvastatin, BiDil (isosorbide dinitrate/hydralazine HCl), Propranolol, Carvedilol, Metoprolol
  • Lifestyle Risk Factors: Diet Pattern, Sleep Depth, Sleep Duration, HDL- Cholesterol, LDL- Cholesterol, Triglycerides, BMI/Obesity, Blood Pressure, Alcoholism, Homocysteine Levels, Response to Exercise, Alcohol Flush Reaction, Nicotine Dependence

Why choose MyDNA Cardio Geneguard ?

  • Early Risk Assessment: Detect and assess the risk of Cardiovascular Diseases (CVDs) and diabetes before symptoms arise, enabling timely intervention
  • Comprehensive Insights: Gain a deep understanding of your genetic predisposition to common cardiovascular diseases such as atrial fibrillation, coronary heart disease, heart attack, stroke, as well as insights into obesity and lipid metabolism imbalances.
  • Personalised Recommendations: Receive tailor-made recommendations for lifestyle modifications based on your unique genetic profile. This personalised approach is designed to help you reduce the risk and effectively manage chronic conditions, promoting overall well-being.

Who should take MyDNA Cardio Geneguard ?

  • Individuals with a family history of Cardiovascular Diseases (CVDs).
  • People managing conditions like diabetes, hypertension, or blood pressure.
  • Those with unhealthy or stressed lifestyles.
  • Individuals planning for family health.
  • Anyone seeking proactive health management.

How Do We Analyse?

Polygenic Risk Score

Based on Polygenic Risk Score (PRS), this report is generated. A polygenic risk score (PRS) estimates an individual’s genetic risk (predisposition) for a trait or condition. PRS takes the sum (aggregate) of SNPs to calculate an overall genetic risk for a particular condition.

How it works?

Order a Kit

Gather saliva samples.Make sure the cap is securely fastened

Document the sample And Reach us @ 040-49583100 to collect your samples

Lab Processing & Data Analysis

Report Generation

Login in your account or check your email

Schedule your Genetic Counselling

References :
  1. Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, Joshi S, Bajaj S, Jabbar PK, Das HK, Kumar A, Dhandhania VK, Bhansali A, Rao PV, Desai A, Kalra S, Gupta A, Lakshmy R, Madhu SV, Elangovan N, Chowdhury S, Venkatesan U, Subashini R, Kaur T, Dhaliwal RS, Mohan V; ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jun 7:S2213-8587(23)00119-5. doi: 10.1016/S2213-8587(23)00119-5.
  2. Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016 Apr 19;133(16):1605-20. doi: 10.1161/CIRCULATIONAHA.114.008729.
  3. Chaturvedi V, Parakh N, Seth S, Bhargava B, Ramakrishnan S, Roy A, et al. Heart failure in India: The INDUS (INDia Ukieri Study) study. J Pract Cardiovasc Sci 2016;2:28-35.